par Demeestere, Isabelle 
Référence Medecine Therapeutique Medecine de la Reproduction, Gynecologie et Endocrinologie, 20, 1, page (24-31)
Publication Publié, 2018-01
Référence Medecine Therapeutique Medecine de la Reproduction, Gynecologie et Endocrinologie, 20, 1, page (24-31)
Publication Publié, 2018-01
Article révisé par les pairs
| Résumé : | Information about infertility risks and fertility preservation options should be provide for all patients who receive gonadotoxic treatments. However, efforts to apply this recommendation from International Scientific Societies are mainly focused on oncological patients and in a lesser extent on patients diagnosed with benign diseases, including hematological benign diseases, auto-immune diseases, gynecological or genetic disorders. However, these indications count for 8 to 19 % of the fertility preservation demands and the risk of premature ovarian failure due to the treatment or the disease itself can be considered as high for several young patients. Counseling and adequate management of these patients might require particular attention due to severe healthy conditions that can be observed in some auto-immune diseases. In this revue, we address the specific issues of each non-oncological indication based on the literature and on personal experience. |
